University of Queensland coronavirus vaccine appears to be safe and effective

The University of Queensland coronavirus vaccine trial is nearing completion, as researchers warn that the jab appears to be safe and effective in the elderly.

Health Minister Greg Hunt announced the trial’s promising progress on Friday, which is ahead of schedule.

“The initial data is very clear, that the vaccine is proving to be safe through phase I clinical trials and that it is proving to produce a positive antibody response.

That means it is doing its job. That is particularly true in the elderly, and that is an especially important finding, given the global vulnerability to the elderly around the world from COVID-19. ‘

University of Queensland Coronavirus Vaccine Trial Is Making Positive Progress

Mr. Hunt said that global biotechnology company CSL has completed manufacturing the vaccine for phase three of the clinical trials.

“That may come as a positive surprise to many people here in Australia and around the world, but what it shows is that we were ahead of schedule,” he said.

Hunt said the vaccine will potentially be available in the third quarter of 2021, if all goes well with the remaining trials.

“Our national goal is to ensure that all Australians seeking to get vaccinated are vaccinated by the end of 2021,” he said.

“All of these developments are now being bolstered by the data coming in, showing strong safety and robust results in terms of T-cell and antibody response.

“In other words, vaccines are on their way to doing what they are expected to do, which is to save lives and protect them.”

Health Minister Greg Hunt will inspect the lab on Friday, where he is expected to announce the promising signs seen in the trial, which is reportedly ahead of schedule.

The effectiveness in older Australians comes after it was suggested that older and pregnant women would miss the first few doses of the Pfizer Covid-19 vaccine.

Pfizer has a 90 percent effectiveness rate in late-stage clinical trials, and Australia signed a deal for 10 million doses.

However, due to its method of administration, it is not considered safe enough for the elderly and vulnerable.

UQ associate professor Paul Griffin said the results are exciting, but he was cautious as it is still early.

For vaccines and clinical trials, it is necessary to wait until the trial is complete and the data is analyzed and published. We haven’t got there yet, ‘he said at Sunrise on Friday morning.

“This is an intermediate result, but with that said, the interim results indicate that it provides protection and is safe and includes protection for the elderly and is really exciting.”

Infectious disease specialist Sanjaya Senanayake told the show that we should wait for the ‘next step and get the final data before celebrating too much.’

“I think it is a great vaccine,” he said.

“We know that this type of vaccine works well, but it has a lot of innovative technology for clamp technology. Is very good.

“But as Dr. Griffin said earlier, since we are not in the final stages of testing … we should move on to the next step.”

Prime Minister Scott Morrison is seen during a tour of the University of Queensland Vaccine Laboratory on October 12.

Between Pfizer and UQ, Australia has also bought access to AstraZeneca and Novavax.

The National Cabinet will meet again on Friday, with vaccines on the agenda.

Prime Minister Scott Morrison is expected to outline the federal government’s vaccine policy, including requirements for states and territories to help distribute the drugs, if they get approval.

In the image: a health professional prepares a needle during an announcement for the development of a vaccine against coronavirus disease, made by the University of Queensland